SCHEMBL5494622

SCHEMBL5494622

COC(=O)C1(C)CSC(c2ccc(F)cc2)=N1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.36
PKM P14618 1/20 0.36
SLC6A4 P31645 3/20 0.35
SLC6A3 Q01959 3/20 0.35
RAB9A P51151 3/20 0.35
NPC1 O15118 2/20 0.35
CASP3 P42574 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
SENP8 Q96LD8 1/20 0.35
SENP7 Q9BQF6 1/20 0.35
SENP6 Q9GZR1 1/20 0.35
IKBKB O14920 1/20 0.35
NR1H2 P55055 1/20 0.34
LMNA P02545 1/20 0.34
PTGS1 P23219 1/20 0.34
MEN1 O00255 1/20 0.34
GFER P55789 1/20 0.34
KMT2A Q03164 1/20 0.34
OPRK1 P41145 1/20 0.34
PIN1 Q13526 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29438029 0.77 ALDH1A1 (0.39) ALDH1A1
SCHEMBL27635068 0.72 GABRA5 (0.52) LMNAMEN1KMT2APIN1
SCHEMBL6315068 0.71 OPRM1 (0.40) ALDH1A1SLC6A4RAB9ANPC1SMN1; SMN2
SCHEMBL5914841 0.71 GRM6 (0.35) ALDH1A1RAB9ANPC1LMNAMEN1
SCHEMBL6401268 0.71 OPRM1 (0.40) ALDH1A1SLC6A4RAB9ANPC1SMN1; SMN2
SCHEMBL10969254 0.71 KDM4E (0.39) ALDH1A1RAB9ANPC1MEN1KMT2A
SCHEMBL5711476 0.71 MEN1 (0.31) MEN1KMT2A
SCHEMBL6315318 0.70 THRB (0.34) ALDH1A1RAB9ANPC1SMN1; SMN2PIN1
SCHEMBL5914861 0.70 THRB (0.34) ALDH1A1RAB9ANPC1SMN1; SMN2PIN1
SCHEMBL6328828 0.69 DGAT1 (0.32) MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1656360-B1 THIAZOLINE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) JANSSEN PHARMACEUTICA NV (BE) 2007-08-15 EP disclosed
EP-1656360-A1 THIAZOLINE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) JANSSEN PHARMACEUTICA N.V. (BE) 2006-05-17 EP disclosed
US-20050014952-A1 Novel thiazoline derivatives as selective androgen receptor modulators (SARMS) JASSEN PHARMACEUTICA N.V. (BE) 2005-01-20 US disclosed
WO-2004113309-A1 THIAZOLINE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) JANSSEN PHARMACEUTICA N.V. (BE) 2004-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014952-A1 Novel thiazoline derivatives as selective androgen receptor modulators (SARMS) AR, NR5A1, NR5A2 ALDH1A1 512/4885PKM 253/4885SLC6A4 2343/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.